

**PRODUCT INFORMATION**

<b>Common Name</b>	IMGN-529, IMGN529, K7153A-SMCC-DM1
<b>Synonyms</b>	CD37;TSPAN26;Tspan-26
<b>Applications</b>	Flow Cyt
<b>Recommended Dilutions</b>	Flow Cyt 1:100
<b>Formulation &amp; Reconstitution</b>	Lyophilized from sterile PBS, pH 7.4. Normally 5% - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
<b>Host Species</b>	Chimeric
<b>IgG type</b>	IgG1
<b>Reactivity</b>	Human
<b>Target</b>	CD37
<b>Uniprot ID</b>	P11049
<b>Description</b>	Anti-CD37 (naratuximab biosimilar) mAb
<b>Delivery</b>	In Stock
<b>Storage &amp; Shipping</b>	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
<b>Background</b>	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
<b>Usage</b>	Research use only
<b>Conjugate</b>	Unconjugated
<b>DIMA Disclaimer</b>	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.






Figure 1. HEK293 cell line transfected with irrelevant protein (B) and human CD37 (A) were surface stained with Anti-CD37 mAb 1  $\mu$ g/ml (naratuximab) followed by Alexa 488-conjugated anti-human IgG secondary antibody.




Figure 2. Flow cytometry analysis of antigen binding of anti-human CD37 mAb(BME100046).

(A) BME100046 does not bind to 293T cells that do not express CD37.

(B) A clear peak shift of BME100046 was seen compared to the control when incubated with CD37-expressing THP-1 cells, indicating strong binding of BME100046 to CD37. Antibodies were incubated at 5  $\mu$ g/mL.

